Page 546 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.5: Cost comparisons of watchful waiting with active treatments (continued)
Author Design Data Years N Methods Costs WW RP RT Notes
year source Population (95% (95% CI) (95% CI)
UI characteristics CI)
Andersson 237 Substudy of SPCG-4 Recruitment, WW = 105 Medical records Total mean € € 24,247 NA No patient
2011 RCT 1989-99; RP = 107 were cost after 18,124 (NR) was lost to
21265595 followed retrospectively median (NR) follow-up
through July <75 years, life reviewed; a followup of
2007 expectancy >10 healthcare 11.8 yr for the P<0.01 for
years, T0d-T2 provider WW group the absolute
disease, WHO perspective was and 12.2. for difference
well/moderately adopted (costs the RP group between
differentiated, generated from groups,
PSA <50ng/ml, care outside the unadjusted
no evidence of hospital were analysis; in
skeletal not considered); multivariable
metastases on resource use analysis
bone scan; was measured P=0.003
patients from in physical units (adjusted for
the trial were and then age, PSA and
included if they multiplied by the Gleason
resided in the unit cost (based score).
counties where on 2007
the two centers Swedish prices
that converted to €).
randomized
most patients
were located
(Örebro and
Uppsala).
Penson 235 Retrospective CaPSURE 1990-97 WW = 37 Direct costs of Average first RP RT P <0.001 for
2001 cohort study Active Tx = 198 prostate cancer year cost monotherapy monotherapy the treatment
11248628 [RP treatment effect
monotherapy, (outpatient $ 484 $ 7320 (ANCOVA,
RP + visits, laboratory (NR) (NR) $ 7430 adjusted for
neoadjuvant tests and (NR) stage,
hormone procedures, Gleason sum,
therapy; RT prescribed serum PSA at
monotherapy, medications, diagnosis,
RT + surgical insurance
neoadjuvant treatments and status,
hormonal hospitalizations), comorbidities,
therapy; adjusted to 1996 age); cost

C-191